Trial Profile
Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nicotinamide (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 11 Dec 2013 Planned end date changed from 1 Jul 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 28 Jun 2012 Planned end date changed from 1 Apr 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.